Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study investigated an association between the cytochrome P450 (CYP) 2C8*3 polymorphism with asthma symptom control in children and changes in lipid metabolism and pro-inflammatory signaling by human bronchial epithelial cells (HBECs) treated with cigarette smoke condensate (CSC). CYP genes are inherently variable in sequence, and while such variations are known to produce clinically relevant effects on drug pharmacokinetics and pharmacodynamics, the effects on endogenous substrate metabolism and associated physiologic processes are less understood. In this study, CYP2C8*3 was associated with improved asthma symptom control among children: Mean asthma control scores were 3.68 ( = 207) for patients with one or more copies of the CYP2C8*3 allele versus 4.42 ( = 965) for CYP2C8*1/*1 ( = 0.0133). In vitro, CYP2C8*3 was associated with an increase in montelukast 36-hydroxylation and a decrease in linoleic acid metabolism despite lower mRNA and protein expression. Additionally, CYP2C8*3 was associated with reduced mRNA expression of interleukin-6 (IL-6) and C-X-C motif chemokine ligand 8 (CXCL-8) by HBECs in response to CSC, which was replicated using the soluble epoxide hydrolase inhibitor, 12-[[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-dodecanoic acid. Interestingly, 9(10)- and 12(13)- dihydroxyoctadecenoic acid, the hydrolyzed metabolites of 9(10)- and 12(13)- epoxyoctadecenoic acid, increased the expression of IL-6 and CXCL-8 mRNA by HBECs. This study reveals previously undocumented effects of the CYP2C8*3 variant on the response of HBECs to exogenous stimuli. SIGNIFICANCE STATEMENT: These findings suggest a role for CYP2C8 in regulating the epoxyoctadecenoic acid:dihydroxyoctadecenoic acid ratio leading to a change in cellular inflammatory responses elicited by environmental stimuli that exacerbate asthma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11257687 | PMC |
| http://dx.doi.org/10.1124/dmd.124.001684 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Point Application Therapy Targeting Feishu, Pishu and Shenshu Attenuates Asthma by Suppressing Autophagy and the AMPK-mTOR Signalling Pathway.
J Asthma
September 2025
Department of Acupuncture and Moxibustion, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310006, China.
Objective: In traditional Chinese medicine, asthma is associated with deficiencies in Lung Qi, Spleen Qi, and Kidney Qi. This study investigated the therapeutic mechanism of point application therapy focusing on the acupoints Feishu (BL13), Pishu (BL20), and Shenshu (BL23) for asthma treatment.
Methods: An asthma model was established in Wistar rats via intraperitoneal ovalbumin injection combined with nebulisation.
PVC Nanoplastics Exposure Exacerbates Asthma through R-Loop Accumulation and Subsequent STING Activation in Macrophages.
Adv Sci (Weinh)
September 2025
Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, China.
Asthma is a chronic inflammatory respiratory disease influenced by genetic and environmental factors. Emerging evidence suggests that microplastics and nanoplastics (NPs) pose significant health risks. When inhaled, these tiny particles can accumulate in the lungs, triggering inflammation, oxidative stress, and other disruptions in pulmonary function.
View Article and Find Full Text PDFDecoding Dyspnea: Unveiling Malignancy Disguised as Asthma.
Cureus
August 2025
Allergy and Immunology, Wilford Hall Medical Center, San Antonio, USA.
We present two patients who presented with symptoms that overlap with asthma, but upon further diagnostic evaluation, were revealed to have underlying malignancy. These cases highlight the importance of objective evidence-based evaluation in unveiling diagnoses previously mislabeled as asthma. The first patient was a 51-year-old with one year of cough and waning albuterol responsiveness, with worsening orthopnea and exertional dyspnea.
View Article and Find Full Text PDFClinical, functional, and laboratory course of children and adolescents with severe asthma after discontinuation of biologics.
Front Allergy
August 2025
Unit of Pediatric Allergy and Respiratory Medicine, Women's and Children's Health Department, University Hospital of Padova, Padova, Italy.
Background: Although the benefits of biologics in severe asthma are well established, the optimal strategy to discontinue therapy remains controversial.
Aim: to evaluate clinical, functional, and laboratory course of children and adolescents with severe asthma after biological therapy withdrawal due to sustained good control. Secondary aim was to identify clinical or inflammatory markers predictive of asthma control after discontinuation.
Systematic Literature Review of Real-world Outcomes of Benralizumab in Eosinophilic Granulomatosis with Polyangiitis.
J Allergy Clin Immunol Pract
September 2025
Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health, Denver, Colorado, USA. Electronic address:
Background: Several real-world cohorts and numerous case reports investigating benralizumab outcomes in eosinophilic granulomatosis with polyangiitis have been published. These studies complement the limited clinical trial data available by providing early insights on benralizumab use in a broader, real-world population.
Objective: The objective of this systematic literature review (SLR) was to provide an overview of the real-world outcomes of benralizumab in EGPA.